Rottapharm launches high-speed bookbuilding
Italian pharmaceuticals firm Rottapharm launched bookbuilding for a €450m IPO on Wednesday, aiming to find a premium to the sector and running a shorter bookbuilding period than normal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: